Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483721 | 0.86 | HTT (0.64) | HPGDALDH1A1L3MBTL1 | |
| SCHEMBL26417076 | 0.86 | HTT (0.64) | HPGDALDH1A1L3MBTL1 | |
| SCHEMBL28763778 | 0.85 | HPGD (0.53) | HPGDALDH1A1CYP1A2NPC1RAB9A | |
| SCHEMBL4158170 | 0.85 | TAS1R3 (0.64) | HPGDALDH1A1GPR139P2RX7 | |
| SCHEMBL10792384 | 0.85 | HPGD (0.81) | HPGDALDH1A1POLBCYP1A2NPC1 | |
| SCHEMBL10605231 | 0.82 | POLB (0.64) | HPGDALDH1A1POLBCYP1A2NPC1 | |
| SCHEMBL6358749 | 0.82 | HPGD (1.00) | HPGDALDH1A1POLBCYP1A2NPC1 | |
| SCHEMBL13754086 | 0.82 | HPGD (0.51) | HPGDALDH1A1POLBCYP1A2NPC1 | |
| SCHEMBL28214367 | 0.81 | HPGD (0.61) | HPGDALDH1A1POLBCYP1A2NPC1 | |
| SCHEMBL19302643 | 0.81 | HPGD (0.61) | HPGDALDH1A1POLBCYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751123-B1 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS (JP) | 2000-05-10 | — | — | EP | claimed |
| US-5672751-A | TREATMENT OF A HALOBENZAMIDE WITH AN ALKANETHIOL IN THE PRESENCE OF A PHASE TRANSFER CATALYST | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-09-30 | — | — | US | claimed |
| EP-0751123-A2 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-01-02 | — | — | EP | claimed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | claimed |
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220289736-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20200157096-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190055236-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2019-02-21 | — | — | US | disclosed |
| US-5672751-A | TREATMENT OF A HALOBENZAMIDE WITH AN ALKANETHIOL IN THE PRESENCE OF A PHASE TRANSFER CATALYST | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0751123-A2 | Method for producing alkylsulfinylbenzamides | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-5508416-A | HALOGENATING A 2-(ALKYLTHIO)BENZAMIDE, CYCLIZATION TO HETERO RING AND N-S LINKAGE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5498630-A | SUBSTITUTED BENZOTHIOPHENECARBOXAMIDES | MONSANTO COMPANY (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0657438-A2 | Method for producing alkylsulfinylbenzamides and 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1995-06-14 | — | — | EP | disclosed |
| CN-1085221-A | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 1994-04-13 | — | — | CN | disclosed |
| WO-1993007751-A1 | FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS | MONSANTO COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0538231-A1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | HPGD 1183/4885ALDH1A1 3584/4885POLB 4309/4885 |
| US-20220289736-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | HPGD 1183/4885ALDH1A1 3584/4885POLB 4309/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | HPGD 1183/4885ALDH1A1 3584/4885POLB 4309/4885 |
| US-20190055236-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | HPGD 1183/4885ALDH1A1 3584/4885POLB 4309/4885 |
| US-20200157096-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | HPGD 1183/4885ALDH1A1 3584/4885POLB 4309/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | HPGD 1183/4885ALDH1A1 3584/4885POLB 4309/4885 |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | HPGD 951/4885ALDH1A1 284/4885POLB 3400/4885 |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | HPGD 3950/4885ALDH1A1 3113/4885POLB 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.